Dr. Shuaiying Cui is an Associate Professor of Medicine at Boston University and an Adjunct Assistant Professor at the University of Michigan. He obtained his PhD from the University of Science and Technology of China. In addition, he is a member of the Center of Excellence in Sickle Cell Disease, Boston University. His research has focused on the development of novel agents that can elicit developmental stage-specific gene silencing or reprogramming in hematopoietic stem cells and progenitors through a series of epigenetic chromatin modifications by nucleosome remodeling, histone deacetylation, and demethylation.
Dr. Shuaiying Cui is an Associate Professor of Medicine at Boston University and an Adjunct Assistant Professor at the University of Michigan. He obtained his PhD from the University of Science and Technology of China. In addition, he is a member of the Center of Excellence in Sickle Cell Disease, Boston University. His research has focused on the development of novel agents that can elicit developmental stage-specific gene silencing or reprogramming in hematopoietic stem cells and progenitors through a series of epigenetic chromatin modifications by nucleosome remodeling, histone deacetylation, and demethylation.